|
FBXO42 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.02530206547158E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.2734005223366E-10 |
| Normal-vs-Stage2 |
3.63399999999681E-05 |
| Normal-vs-Stage3 |
4.34799973803024E-11 |
| Normal-vs-Stage4 |
1.70159997203712E-09 |
| Stage1-vs-Stage2 |
7.823000E-01 |
| Stage1-vs-Stage3 |
3.598300E-02 |
| Stage1-vs-Stage4 |
9.440200E-02 |
| Stage2-vs-Stage3 |
1.206630E-01 |
| Stage2-vs-Stage4 |
1.529590E-01 |
| Stage3-vs-Stage4 |
9.677800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.80875364370104E-12 |
| Normal-vs-AfricanAmerican |
3.881300E-03 |
| Normal-vs-Asian |
4.08100000015565E-07 |
| Caucasian-vs-AfricanAmerican |
1.647020E-01 |
| Caucasian-vs-Asian |
3.445000E-01 |
| AfricanAmerican-vs-Asian |
4.819400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.61680002719322E-09 |
| Normal-vs-Female |
3.19609894106065E-11 |
| Male-vs-Female |
8.615000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.23670004739773E-09 |
| Normal-vs-Age(41-60Yrs) |
2.640699992007E-09 |
| Normal-vs-Age(61-80Yrs) |
7.32910399037223E-11 |
| Normal-vs-Age(81-100Yrs) |
4.590600E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.891200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.590300E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.730600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.831400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.417200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.418400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.55920000000687E-05 |
| Classical-VS-Follicular |
4.078800E-01 |
| Classical-VS-Other |
3.695200E-01 |
| Classical-VS-Normal |
1.2784999725568E-09 |
| Tall-VS-Follicular |
9.400700E-03 |
| Tall-VS-Other |
3.247000E-01 |
| Tall-VS-Normal |
6.01863003879544E-12 |
| Follicular-VS-Other |
6.573400E-01 |
| Follicular-VS-Normal |
6.94020000024942E-07 |
| Other-VS-Normal |
2.302000E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.77030001768941E-09 |
| Normal-vs-N1 |
3.75310005296114E-10 |
| N0-vs-N1 |
8.543900E-02 |
|
|
